Eli Lilly's (LLY) Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Importance
Level 1
- The primary endpoint of this study was a SALT score ≤20 at Week 36
#ELI LILLY & CO#LLY.US#EUROPEAN UNION#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES